INC Research Announces Multi-Year Strategic Clinical Development Alliance with Astellas
INC Research announced that the company has entered into a Functional Service Provider (FSP) alliance with Astellas Pharma Global Development, Inc.(Astellas), to drive global consistency, save time, and reduce costs for multiple clinical development programs across several therapeutic areas. In an initial three-year agreement, INC Research will deliver key functional services to Astellas, including Clinical Monitoring,Clinical Data Management, Trial Master File Management, Site Start-up and Study Feasibility activities. Work began April 2 and is being conducted globally.
"INC Research has worked with Astellas on several full-service development programs where our teams have created strong bonds and deep level of trust, and we are excited to extend that relationship through our FSP alliance," said James Ogle, CEO, INC Research. "With mutually agreed expectations and insight into Astellas' development pipeline, our dedicated teams will utilize our innovative tools and proprietary processes to efficiently manage these clinical development elements and drive global consistency across development programs."
INC Research established a dedicated business unit for delivery of the FSP services to Astellas, allowing for independent, cross-functional resource management and training of Company staff committed to the partnership. An executive governance structure has been implemented for management of the relationship, with plans to leverage key metrics to drive decision making and ensure continuous improvement across the alliance. Success will be measured based on operational delivery, effectivecollaboration and process and technology innovation.
INC Research is among the pioneers involved in development of the FSP model, providing more than a decade of FSP experience and the expertise of hundreds of dedicated and highly experienced FSP employees. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas for its biopharmaceutical customers. The end result is greater cost predictability and delivery of consistent services across all protocols. INC Research's FSP model has proven to reduce costs by up to 40 percent and generate time savings of 10 to 20 percent over the course of a relationship.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
